How to Reconstitute Tirzepatide for In Vitro Research

To reconstitute research tirzepatide, add a measured volume of sterile water or bacteriostatic water to the lyophilized powder, swirl gently until clear, and record the concentration. For many researchers, though, reconstitution is only the first step: the stock then has to be converted to molar units and diluted into an assay buffer without losing the peptide to surfaces. This guide covers both stages.

For laboratory research use only. The compounds discussed are not approved for human or veterinary use and are not drugs, foods or cosmetics. This article summarises published research and is not medical advice.

Key points

Stock: sterile or bacteriostatic water, gentle swirling, clear and colourless result.
Molecular weight 4813.53 Da: 1 mg/mL ≈ 208 µM.
The licensed product is phosphate-buffered with sodium chloride; plain-water stocks are unbuffered.
At nanomolar working concentrations, use low-binding plastics and a carrier protein.
Store stocks at 2–8 °C; freeze only single-use aliquots in sterile water.

Reference point: the licensed formulation

The U.S. prescribing information gives a useful benchmark for what a well-formulated tirzepatide solution looks like:

Attribute	Licensed product	Typical research stock
Appearance	Clear, colourless to slightly yellow	Clear, colourless
Excipients	Sodium chloride, sodium phosphate dibasic, water for injection	Water (± 0.9% benzyl alcohol)
Buffering	Phosphate	None; pH set by peptide salt
Molecular weight	4813.53 Da (C₂₂₅H₃₄₈N₄₈O₆₈)

The difference in buffering matters. A review of peptide formulation identifies pH control and buffer choice as the most practical ways to slow degradation in solution (Nugrahadi et al., 2023). An unbuffered research stock should therefore be kept cold and used within a conservative period.

Preparing the stock solution

Warm the sealed vial to room temperature.
Swab stoppers and let them dry.
Add solvent slowly down the vial wall; swirl, do not shake.
Confirm a clear, colourless solution with no strands or particles.
Label and refrigerate.

Tirzepatide carries a C20 fatty diacid. In vivo this binds albumin; in vitro the amphiphilic structure makes the peptide prone to self-association. If bacteriostatic water produces persistent haze, consider sterile water instead, since antimicrobial preservatives have been shown to drive aggregation of an acylated peptide (Li et al., 2022).

From mg/mL to molar units

Vial	Solvent	mg/mL	Molar concentration
5 mg	1.0 mL	5	1.04 mM
10 mg	2.0 mL	5	1.04 mM
10 mg	1.0 mL	10	2.08 mM
20 mg	2.0 mL	10	2.08 mM
30 mg	3.0 mL	10	2.08 mM

Formula: µM = (mg/mL ÷ 4813.5) × 1,000,000. If the COA reports net peptide content below 100%, multiply by that fraction for accurate molar work. The peptide reconstitution calculator handles the mg/mL step.

Diluting for cell-based assays

Receptor signalling assays typically use picomolar to nanomolar concentrations; the discovery work on tirzepatide characterised GIP and GLP-1 receptor activation in cell lines expressing recombinant or endogenous receptors (Coskun et al., 2018). Going from a millimolar stock to nanomolar working solutions requires serial dilution:

Step	From	Dilution	To
1	2.08 mM stock	1:100	20.8 µM
2	20.8 µM	1:100	208 nM
3	208 nM	1:10 series	20.8 nM → 2.08 nM → 208 pM …

Practical tips for these dilutions:

Use low-binding tubes and tips. At nanomolar concentrations, a significant fraction of a lipidated peptide can adsorb to standard polypropylene.
Add a carrier protein (for example 0.1% BSA) to dilution buffers, unless it interferes with the assay. Note that albumin binds the fatty acid and shifts apparent potency, which is itself a known variable in incretin assays.
Avoid vortexing; air–water interfaces promote aggregation, especially at low concentration (Treuheit et al., 2002).
Prepare working dilutions fresh each day.

Storage

Material	Condition
Lyophilized powder	−20 °C, sealed, dark
Stock solution (in use)	2–8 °C, dark; date the vial
Stock for longer storage	Single-use aliquots in sterile water, low-binding tubes, frozen once
Working dilutions	Prepare fresh; discard at end of day

Our tirzepatide research peptide is supplied in 5–60 mg vials with HPLC and MS data per lot. For general technique, see how to reconstitute peptides.

Related research

Frequently asked questions

How do you reconstitute tirzepatide powder?

Let the vial reach room temperature, add a measured volume of sterile water or bacteriostatic water slowly down the vial wall, and swirl gently until the solution is clear. Record the concentration and date, and refrigerate.

How do I convert tirzepatide mg/mL to micromolar?

Divide the concentration in mg/mL by 4813.5 (the molecular weight in g/mol) and multiply by 1,000,000. For example, 1 mg/mL is about 208 µM, and 10 mg/mL is about 2.08 mM.

What buffer is used in the licensed tirzepatide formulation?

According to the U.S. prescribing information, the licensed solution contains sodium chloride and sodium phosphate dibasic in water for injection. Research reconstitution in plain water lacks this buffering.

Why does diluted tirzepatide lose activity in assays?

At nanomolar concentrations, lipidated peptides adsorb to plastic and glass surfaces. Low-binding tubes and an assay buffer containing a carrier protein such as BSA reduce these losses.

What colour is reconstituted tirzepatide?

Clear and colourless. The licensed product is described as clear, colourless to slightly yellow.

References

DailyMed. Tirzepatide injection, solution — U.S. prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
Coskun T, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018. PMID: 30473097 https://pubmed.ncbi.nlm.nih.gov/30473097/
Li M, et al. Molecular Mechanism of Antimicrobial Excipient-Induced Aggregation in Parenteral Formulations of Peptide Therapeutics. Mol Pharm. 2022. PMID: 35917158 https://pubmed.ncbi.nlm.nih.gov/35917158/
Nugrahadi PP, et al. Designing Formulation Strategies for Enhanced Stability of Therapeutic Peptides in Aqueous Solutions: A Review. Pharmaceutics. 2023. PMID: 36986796 https://pubmed.ncbi.nlm.nih.gov/36986796/
Treuheit MJ, et al. Inverse relationship of protein concentration and aggregation. Pharm Res. 2002. PMID: 12033388 https://pubmed.ncbi.nlm.nih.gov/12033388/